LGALS9 and pancreatic ductal adenocarcinoma: Gal-9 emerges as a pivotal modulator within the tumor immune microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC), orchestrating immunosuppressive mechanisms that promote tumor progression and therapy resistance Figure 1.